The abundant nuclear enzyme poly(ADP-ribose)polymerase-1 ( PARP -1) represents an important novel target in cancer therapy. PARP -1 is essential to the repair of single strand DNA breaks via the base excision repair pathway. Inhibitors of PARP -1 have been shown to enhance the cytotoxic effects of ionising radiation and DNA damaging chemotherapy agents such as the methylating agents and topoisomerase-I inhibitors. There are currently at least eight PARP inhibitors in clinical trial development. In vitro data, in vivo preclinical data and most recently early clinical trial data suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers but also as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer associated (BRCA)1 and BRCA2 genes. This theory of selectively exploiting cells defective in one DNA repair pathway by inhibiting another is a major breakthrough in the treatment of cancer. The current clinical data are discussed within this review with reference to the preclinical models which predicted activity and also future directions and the possible dangers/pitfalls of this clinical strategy are explored.
作 者
学科领域 生物医药 » 药学
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer
浙公网安备 33010202000686号 ( 浙ICP备09035230号-1 )
